Pharmacopeia — Investor Day (November 2007)
7 slides from Pharmacopeia's investor day presentation, Nov 14, 2007
Slide 1: Lab Day Introduction
Discovering excellence, driving clinical successTM Lab Day Introduction Leslie J. Browne November 14th, 2007
Slide 2: Forward-Looking Statements
Forward-Looking Statements . This presentation, and oral statements made with respect to information contained in this presentation, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which e
Slide 3: Achieving Clinical Milestones
Achieving Clinical Milestones First-In-Class DARA Program Initiated Phase 2 Proof of Concept study Phase 1 SARM in-licensed Potentially best-in-class Plan to be in Phase 2 by 1Q-09 Partners’ Results Upcoming CXCR2 antagonist in Phase 2 p38 kinase inhibitor in Phase 2 CCR1 Development Candidate Candi
Slide 4: Deep, High Quality, Diversified Portfolio
Muscle Wasting SARM PS178990 Cardiovascular DARA PS433540 Immuno/Inflam JAK3 Parkinson’s Adenosine A2A Rheumatoid/MS CCR1 Derm/Ocular JAK3 Topical Inflammation PS873266 Undisclosed PS015146 Metabolic Disease PS248288 Respiratory PS948115 Inflammation PS386113 Oncology PS095760 Psoriasis/RA p38 PS540
Slide 5: Snapshot: 2006 vs. 2007
Snapshot: 2006 vs. 2007 Financial $3.79 15.3M Shares $57M MC 2 analysts: Canaccord, MCF Clinical Pipeline Strategic Alliances GSK, CEPH Financial $5.72 29.6M Shares $169M Mkt Cap 4 analysts: Canaccord, MCF, CIBC, Broadpoint (First Albany) Clinical Pipeline Strategic Alliances GSK, CEPH, Organon, WYE
Slide 6: Continuing News Flow in 2007 - 2009
Continuing News Flow in 2007 - 2009 4Q:07 2H:08 DARA: Endothelin challenge study initiated CCR1 antagonist for RA and MS chosen for development SARM: Initiate Phase 1 MAD study 1Q:08 DARA: Phase 2a Proof of Concept study results DARA: 2nd Phase 2 hypertension study initiated 2Q:08 1H:09 SARM: Initia
Slide 7: Discovering excellence, driving clinical success
Discovering excellence, driving clinical successTM